Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27269193 | 0.88 | ITGB3 (0.43) | ALDH1A1ITGB3ITGA2BGNAI3GNAO1 | |
| SCHEMBL4001046 | 0.83 | ALDH1A1 (0.41) | ALDH1A1ITGB3ITGA2BCYP2C9CYP2C19 | |
| SCHEMBL17626803 | 0.81 | ITGB3 (0.39) | ITGB3ITGA2BCYP2C9CYP2C19HTR2B | |
| SCHEMBL785724 | 0.81 | AKR1C3 (0.43) | ITGB3ITGA2BMEN1KMT2AGNAI3 | |
| SCHEMBL4599331 | 0.79 | ITGB3 (0.49) | ALDH1A1ITGB3ITGA2BMEN1KMT2A | |
| SCHEMBL1710845 | 0.79 | CHRM2 (0.49) | ITGB3ITGA2BMEN1KMT2AGNAI3 | |
| SCHEMBL12016032 | 0.79 | GNAI3 (0.45) | ITGB3ITGA2BCYP2C9MEN1KMT2A | |
| SCHEMBL1898526 | 0.79 | ITGB3 (0.38) | ALDH1A1ITGB3ITGA2BMEN1KMT2A | |
| SCHEMBL760154 | 0.79 | ITGB3 (0.38) | ALDH1A1ITGB3ITGA2BMEN1KMT2A | |
| SCHEMBL3119356 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2AGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419427-B1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | ASTEX THERAPEUTICS LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-8481531-B2 | Bicyclic heterocyclyl derivatives as FGFR kinase inhibitors for therapeutic use | ASTEX THERAPEUTICS LTD (GB) | 2013-07-09 | — | — | US | disclosed |
| EP-2419427-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | Astex Therapeutics Ltd. (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20120035171-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2010119284-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | ASTEX THERAPEUTICS LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035171-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | FGFR1, FGFR2, FGFR3 | ALDH1A1 902/4885ITGB3 3231/4885ITGA2B 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.